4 Clinical Practice Guideline – Updated October 2019 Clinical Practice Guideline MULTIPLE YELOMA Table 3: Myeloma defining events. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:The NCCN Clinical staff listed below discloses no relevant financial relationships:NCCN designates this enduring material for a maximum of 0.75 NCCN designates this educational activity for a maximum of 0.79 contact hours.NCCN designates this knowledge-based continuing education activity for 0.75 contact hours (0.075 CEUs) of continuing education credit. Unable to load your delegates due to an error The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, evaluation, treatment, including supportive-care, and follow-up for patients with myeloma. UAN: 0836-0000-18-040-H01-P3025 Chemical Road, Suite 100, Plymouth Meeting, PA 19462 • Phone: 215.690.0300 • Fax: 215.690.0280

Inherent in any amount is the incentive to maintain or increase the value of the relationship.Faculty presentations may include discussion of off-label use. Sheridan PubFactory END ORGAN DAMAGE (CRAB) C-Increased calcium level Corrected serum Calcium >0.25mmol/l above the upper limit of normal or >2.75mmol/l R-Renal insufficiency Creatinine clearance <40 mL per min or serum creatinine >177 μmol/L (>2 mg/dL) A-Anaemia Hb … 2020 Feb 29;5(1):11. doi: 10.1038/s41392-020-0107-0.Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, Bladé J, Goldschmidt H, Weisel KC, Ramasamy K, Zweegman S, Spencer A, Huang JSY, Lu J, Sunami K, Iida S, Chng WJ, Holstein SA, Rocci A, Skacel T, Labotka R, Palumbo A, Anderson KC.Blood Cancer J. These NCCN Guidelines Insights highlight the important updates/changes specific to the myeloma … The heterogeneity of relapsed/refractory multiple myeloma (MM) and an increasing number of therapeutic options in this setting has resulted in a complex environment for treatment decisions. Unable to load your collection due to an error Multiple factors need to be considered when determining the next best therapy. Version 1.2020. 2020 Jun;29(6):1419-1431. doi: 10.1007/s11136-019-02392-6. Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R.J Natl Compr Canc Netw.

Clipboard, Search History, and several other advanced features are temporarily unavailable. NCCN Guidelines® Updates: Management of Multiple Myeloma. Target Audience. 2019 Oct 1;17(10):1154-1165. doi: 10.6004/jnccn.2019.0049.Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R; National Comprehensive Cancer Network.J Natl Compr Canc Netw. These updated ESMO Clinical Practice Guidelines cover the diagnosis and pathology/molecular biology, staging and risk assessment and response evaluation of multiple myeloma. At the NCCN 2019 Annual Congress: Hematologic Malignancies, Dr. Castillo provided recommendations for navigating these complex treatment scenarios in R/R MM. The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, evaluation, treatment, including supportive-care, and follow-up for patients with myeloma. 2020 Jul 13;12(13):13668-13683. doi: 10.18632/aging.103490. From the NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma. Footnote e added here and as appropriate throughout the guidelines: See Principles of Imaging (MYEL-B). These NCCN Guidelines Insights highlight the important updates/changes specific to the myeloma therapy options in the 2018 version of the NCCN Guidelines. Epub 2020 Jul 13.Signal Transduct Target Ther. 2016 Apr;14(4):389-400. doi: 10.6004/jnccn.2016.0046.Kumar SK, Callander NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Cornell RF, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Holmberg L, Htut M, Huff CA, Kang Y, Landgren O, Malek E, Martin T, Omel J, Raje N, Sborov D, Singhal S, Stockerl-Goldstein K, Tan C, Weber D, Johnson-Chilla A, Keller J, Kumar R.J Natl Compr Canc Netw. The National Comprehensive Cancer Network (NCCN) has adopted these guidelines; however, they lack validation. This site needs JavaScript to work properly.